Givix vet 25 mg/ml oraaliliuos Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

givix vet 25 mg/ml oraaliliuos

ceva santÉ animale - clindamycin hydrochloride - oraaliliuos - 25 mg/ml - klindamysiini

BENDAMUSTINE INTAS 2.5 mg/ml kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

bendamustine intas 2.5 mg/ml kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos

intas pharmaceuticals limited - bendamustinum hydrochloridum - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 2.5 mg/ml - bendamustiini

DUTASTERIDE ACCORD 0.5 mg kapseli, pehmeä Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

dutasteride accord 0.5 mg kapseli, pehmeä

accord healthcare b.v. accord healthcare b.v. - dutasteridum - kapseli, pehmeä - 0.5 mg - dutasteridi

Gastazole vet 370 mg/g oraalipasta Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

gastazole vet 370 mg/g oraalipasta

chanelle pharmaceuticals manufacturing limited - omeprazole - oraalipasta - 370 mg/g - omepratsoli

Onsenal Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

onsenal

pfizer limited - selekoksibi - adenomatous polyposis coli - antineoplastiset aineet - onsenal on tarkoitettu adenomaattisen suolen polyyppien määrän vähentämiseen familiaalisessa adenomatoottisessa polyposiitissa (fap) leikkauksen ja endoskooppisen valvonnan lisäksi (ks. kohta 4. vaikutus onsenalia aiheuttama vähennys polyyppi taakkaa riskiä suoliston syöpä ei ole osoitettu (ks. kohdat 4. 4 ja 5.

Bupropion Accord 300 mg säädellysti vapauttava tabletti Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

bupropion accord 300 mg säädellysti vapauttava tabletti

accord healthcare b.v. - bupropion hydrochloride - säädellysti vapauttava tabletti - 300 mg - bupropioni

Imatinib Accord Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

imatinib accord

accord healthcare s.l.u. - imatinibi - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinibi - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. paitsi äskettäin diagnosoitu kroonisen vaiheen kml, ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia. .

Sumatriptan Accord 50 mg tabletti, kalvopäällysteinen Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

sumatriptan accord 50 mg tabletti, kalvopäällysteinen

accord healthcare b.v. - sumatriptan succinate - tabletti, kalvopäällysteinen - 50 mg - sumatriptaani

Sumatriptan Accord 100 mg tabletti, kalvopäällysteinen Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

sumatriptan accord 100 mg tabletti, kalvopäällysteinen

accord healthcare b.v. - sumatriptan succinate - tabletti, kalvopäällysteinen - 100 mg - sumatriptaani

DIAZEPAM ACCORD 5 mg tabletti Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

diazepam accord 5 mg tabletti

accord healthcare b.v. accord healthcare b.v. - diazepamum - tabletti - 5 mg - diatsepaami